Bosh sahifaABBV34 • BVMF
add
AbbVie
Yopilish kursi
62,36 R$
Kunlik diapazon
62,76 R$ - 64,74 R$
Yillik diapazon
40,77 R$ - 74,95 R$
Bozor kapitalizatsiyasi
312,70 mlrd USD
Oʻrtacha hajm
1,45 ming
Yangiliklarda
Investor's Business Daily
1 kun oldin
AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback
3,04%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 14,46 mlrd | 3,83% |
Joriy xarajat | 6,07 mlrd | 21,67% |
Sof foyda | 1,56 mlrd | -12,20% |
Sof foyda marjasi | 10,80 | -15,43% |
Har bir ulushga tushum | 3,00 | 1,69% |
EBITDA | 6,26 mlrd | -8,02% |
Amaldagi soliq stavkasi | 24,95% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 7,28 mlrd | -45,18% |
Jami aktivlari | 143,42 mlrd | 5,29% |
Jami passivlari | 137,35 mlrd | 10,68% |
Umumiy kapital | 6,07 mlrd | — |
Tarqatilgan aksiyalar | 1,77 mlrd | — |
Narxi/balansdagi bahosi | 18,29 | — |
Aktivlardan daromad | 7,33% | — |
Kapitaldan daromad | 13,48% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 1,56 mlrd | -12,20% |
Operatsiyalardan naqd pul | 5,45 mlrd | -28,08% |
Sarmoyadan naqd pul | -8,26 mlrd | -2 137,40% |
Moliyadan naqd pul | -3,07 mlrd | -15,45% |
Naqd pulning sof oʻzgarishi | -5,87 mlrd | -229,70% |
Boʻsh pul | 5,50 mlrd | -26,01% |
Haqida
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Tashkil etilgan
1-yan, 2013
Sayt
Xodimlar soni
50 000
